Zylox-Tonbridge Medical Technology Co., Ltd. (02190.HK) disclosed that the authorized share capital of its H shares rose from 322,400,744 to 336,350,744, while domestic shares remained at 7,781,257. This resulted in a total authorized share capital of 344,132,001. The number of H shares in issue, excluding treasury shares, grew from 315,804,613 to 329,504,613 during November 2025, and treasury shares increased from 6,596,131 to 6,846,131.

The change largely stemmed from the 2025 Share Incentive Scheme, which granted 13,950,000 Restricted Share Units during the month. Additionally, 250,000 H shares were repurchased and classified as treasury shares, reflecting the net increase in treasury holdings. The data provided indicates that the total improvement in issued H shares (excluding treasury shares) amounted to 13,700,000 over the reporting period, with the new total reaching 336,350,744 H shares by the end of November 2025.